LEE S PHARMACEUTIC.

LEE S PHARMACEUTIC. Share · KYG5438W1116 · A12CU5 (XHKG) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak

Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of LEE S PHARMACEUTIC.
No Price
30.04.2026 20:00
Current Prices from LEE S PHARMACEUTIC.
ExchangeTickerCurrencyLast TradePriceDaily Change
OTC: UTC
UTC
LPCUF
USD
30.04.2026 20:00
0,19 USD
0,00 USD
Invested Funds

The following funds have invested in LEE S PHARMACEUTIC.:

Fund
iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF USD (Dist)
Vol. in million
15,92
Percentage (%)
0,02 %
Company Profile for LEE S PHARMACEUTIC. Share
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Aloxi and Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renaltransplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution to treat primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

Company Data

Name LEE S PHARMACEUTIC.
Company Lee's Pharmaceutical Holdings Limited
Website https://www.leespharm.com
Primary Exchange XHKG HKEX
WKN A12CU5
ISIN KYG5438W1116
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Siu Fong Lee
Market Capitalization 112 Mio
Country Hong Kong
Currency EUR
Employees 1,0 T
Address Building 20E, Sha Tin
IPO Date 2021-07-16
Dividends from 'LEE S PHARMACEUTIC.'
Ex-Date Dividend per Share
16.09.2025 0,003 USD
30.05.2025 0,03 HKD
12.09.2024 0,003 USD
28.05.2024 0,001 USD
12.09.2023 0,001 USD
25.05.2023 0,001 USD
08.09.2022 0,001 USD
26.05.2022 0,004 USD
15.09.2021 0,004 USD
31.05.2021 0,03 HKD

Ticker Symbols

Name Symbol
Over The Counter LPCUF
Frankfurt L1PA.F
More Shares
Investors who hold LEE S PHARMACEUTIC. also have the following shares in their portfolio:
CHANG TYPE Industrial Co., Ltd.
CHANG TYPE Industrial Co., Ltd. Share
WISDOMTREE SUGAR
WISDOMTREE SUGAR ETC